Targeting different domains of gap junction protein to control malignant glioma

Jun Wang1,2, Ze-Yu Yang1,2, Yu-Feng Guo1,2

  • 1Institute of Pathology and Southwest Cancer Center, Southwest Hospital, The Third Military Medical University, Chongqing, China.

Neuro-Oncology
|November 7, 2017
PubMed

Insights

Targeting connexin 43 (Cx43) domains offers a promising strategy for glioma treatment. Modulating Cx43

Area of Science:

  • Neuro-oncology
  • Cellular biology
  • Molecular medicine

Background:

  • Glioma, a common primary central nervous system tumor, presents challenges due to invasive growth and therapeutic resistance.
  • Connexin 43 (Cx43), a gap junction protein, is implicated in both central nervous system development and glioma progression.

Purpose of the Study:

  • To review the structural characteristics of Cx43 and its distinct functional domains.
  • To explore the impact of regulating different Cx43 domains on glioma cell biology.
  • To summarize intervention strategies targeting Cx43 domains for glioma treatment.

Main Methods:

  • Review of existing literature on Cx43 structure and function in glioma.
  • Analysis of studies investigating the effects of Cx43 domain modulation on glioma cell invasion and proliferation.
  • Synthesis of current and emerging therapeutic strategies targeting Cx43.

Main Results:

  • Different structural domains of Cx43 (extracellular loops, transmembrane domains, intracellular carboxyl terminus) exhibit distinct roles in glioma invasion and proliferation.
  • Targeting these specific Cx43 domains can inhibit glioma cell invasion and the formation of new tumors.
  • Cx43 expression patterns vary within heterogeneous glioma cell populations, influencing therapeutic approaches.

Conclusions:

  • Targeting specific domains of connexin 43 presents a rational therapeutic strategy for glioma.
  • Understanding the differential roles of Cx43 domains is crucial for developing effective anti-glioma interventions.
  • Future research should focus on refining domain-specific targeting strategies for improved glioma treatment outcomes.